Abstract Recent studies indicate the presence of systemic inflammation in psoriatic patients, and this inflammatory status is significantly associated with a range comorbidities. The aim study was to evaluate clinical significance novel biomarkers, neutrophil–lymphocyte ratio ( NLR ), platelet–lymphocyte PLR ) mean platelet volume MPV Japanese patients plaque‐type psoriasis (PsV) arthritis (PsA). One hundred eighty‐six PsV 50 PsA treated biologics, including infliximab, adalimumab...

Abstract The ratio of the elderly among psoriasis patients has been increasing. However, satisfactory long‐term management for is challenging because more frequent presence comorbidities, and higher risk adverse events from systemic therapeutic agents than younger patients. use ustekinumab ( UST ) appears to be an appropriate treatment it considered less likely cause other treatments, as well necessitating fewer hospital visits. Our retrospective study aimed evaluate efficacy safety profile...

Clinically, patients' adherence to biologic treatment is not only related efficacy but also adverse events, cost and other factors. To evaluate long-term viability of treatment, both the percentage reasons for discontinuation were investigated. In this study, patients treated with infliximab (n = 38), adalimumab 59) ustekinumab 30) included observed 12 months. Clinical was evaluated using a 75% reduction Psoriasis Area Severity Index score (PASI-75), who discontinued considered as having...

Efficacy and safety profiles of biologics have been established for moderate to severe psoriasis. However, inefficacy or adverse events sometimes require changing the treatment other biologics. Here, we examine effectiveness this strategy. We retrospectively investigated cases requiring switching enrolled 275 psoriatic patients treated with between January 2010 December 2014 in our hospital. Of these, 51 required a switch another biologic. First-line therapies were infliximab (IFX, n = 26),...

Inflammation is characterized by altered cytokine levels produced cell populations in a highly interdependent manner. To elucidate the mechanism of an inflammatory reaction, we have developed mathematical model for immune interactions via specific, dose-dependent production rates populations. The describes criteria required normal and pathological system responses suggests that alterations can lead to various stable which manifest themselves different disease phenotypes. predicts pairs...

Brodalumab (KHK4827) is a human anti-interleukin-17-receptor A monoclonal antibody. In Japanese patients with moderate-to-severe plaque psoriasis, brodalumab showed rapid and robust efficacy favourable safety profile in 12-week, phase 2, double-blind, randomized controlled trial.To evaluate the long-term of brodalumab, an extension 2 trial psoriasis was performed.Patients received open-label 210 or 140 mg subcutaneously every weeks for 52 weeks. Efficacy measured using Psoriasis Area...

Abstract Therapy with monoclonal antibodies to tumor necrosis factor ( TNF )‐α and the interleukin IL )‐12/23 p40 subunit has significantly improved clinical outcome of patients psoriasis. These inhibit effects target cytokines thus major concern during their use is induction excessive immunosuppression. Recent studies evaluating long‐term efficacy safety biologic therapy in psoriasis have shown no significant appearance serious adverse including infections malignancies. However,...

Abstract Psoriasis has been shown to accompany systemic inflammation. We aimed examine serum C‐reactive protein ( CRP ) levels in Japanese psoriatic patients, and elucidate their long‐term as well short‐term changes by treatment with different biologics. A retrospective study was conducted those who initiated successfully continued the for up 24 months either infliximab, adalimumab or ustekinumab, at psoriasis special clinic of Jikei University School Medicine. total 212 patients were...

Lipocalin-2 (LCN2), a protein secreted mainly by activated neutrophils, has been associated with neurodegeneration, obesity, and inflammatory responses. Serum LCN2 concentration reported elevated in patients psoriasis, but lower atopic dermatitis (AD). Spinal astrocyte-derived was found to be involved enhancement of itch mouse model AD. However, the relationship between psoriasis not determined. Objective. This study examined correlation serum levels degrees psoriasis. concentrations were...

In 2018, ixekizumab (80 mg every 2 weeks [Q2W] beyond Week 12) received approval in Japan for patients with generalized pustular psoriasis (GPP) and erythrodermic (EP). This open-label study evaluated the efficacy safety of Q2W from 12 to 20) Japanese GPP EP.Seven five EP were enrolled. An initial dose 160 (subcutaneous [SC] injection) was followed by 80 SC until 12. Primary endpoint assessed global improvement score (GIS) comparing psoriatic findings, Static Physician Global Assessment,...

Ustekinumab has demonstrated efficacy for psoriasis. However, it is known that approximately 30% of patients have shown insufficient response. The aim the current study to clarify specific clinical factors could be associated with response ustekinumab treatment. We reviewed medical records all who were treated ustekinumab. Psoriasis Area and Severity Index (PASI) score was calculated, evaluated at week 0 16. relationship between patients' background investigated. patients, showed a <74%...

Abstract Background Long‐term management of moderate‐to‐severe psoriasis is usually discussed in terms continuous administration; however, there are many situations clinical practice where treatment may be withdrawn with subsequent retreatment. Objective To assess the course after ixekizumab withdrawal and retreatment, as well effectiveness Japanese patients plaque psoriasis. Methods This single‐arm, open‐label study ( UNCOVER ‐J; NCT01624233) comprised 78 After (160‐mg loading dose, 80 mg...

Purpose To determine the feasibility of dual-energy (DE) computed tomography (CT) with an iodine overlay image (IOI) for evaluation psoriatic arthritis in hand. Materials and Methods Approval from institutional ethics committee written informed consent all patients were obtained. This prospective study included 16 who had psoriasis finger joint symptoms January 2015 to 2016. Contrast material-enhanced (CE) DE CT 1.5-T CE magnetic resonance (MR) imaging performed within 1 month each other....

Abstract Psoriasis is a chronic inflammatory skin disease mainly mediated by T‐helper cell subset, Th17 cells. Recently, increased levels of total serum immunoglobulin (Ig)E have been reported in subset psoriatic patients. Ustekinumab ( UST ) one the most commonly used biologic agents for treatment moderate to severe plaque psoriasis, and previous report also documented effectiveness patients with high IgE levels. We experienced two levels, whom completely improved psoriasis but...

To investigate the relationship between psoriasis and interstitial pneumonia (IP).We analyzed clinical data of patients with treated biologic agents from June 1, 2008, to 30, 2017, retrospectively. Chest computed tomography was performed in 392 before treatment. The characteristics radiographic findings these were evaluated.Of psoriasis, IP detected 8 (2%). Bilateral ground-glass and/or irregular linear (reticular) opacity lower lung zone most common chest finding. Five anti-interleukin (IL)...

We report an exploratory analysis of the efficacy and safety certolizumab pegol (CZP) in Japanese patients with generalized pustular psoriasis (GPP) erythrodermic (EP) (NCT03051217).Patients ≥ 20 years GPP or EP were randomized 1:1 to open-label CZP 400 mg every 2 weeks (Q2W) 200 Q2W (400 0/2/4) for 16 weeks; who achieved "much improved" "very much on Global Improvement Score (GIS; GPP) a PASI 50 response (≥ 50% reduction from baseline Psoriasis Area Severity Index; EP) continued week 52....

Abstract Palmoplantar pustulosis ( PPP ) often shows resistance to treatment. Vitamin D 3 analog (VitD has been widely used for the treatment of psoriasis, however, efficacy and safety topical VitD are not fully confirmed. Maxacalcitol ointment (22‐oxacalcitriol [ OCT ]) was applied twice daily 8 weeks. Evaluation based on scored skin findings three main symptoms (erythema, pustules/vesicles keratinization/scales). The primary secondary end‐points were total symptom‐specific scores findings,...

Abstract The number of elderly patients with psoriasis is increasing in Japan. However, biologic treatment generally considered to be challenging patients, due their increased risk complications compared younger patients. Our retrospective study aimed evaluate the safety profile and efficacy biologics senior (≥75 years old) psoriasis. involved a cohort 27 aged 75–88 who were being treated over period more than 1 year. Initial administrated adalimumab (five cases) ustekinumab (22 cases)....

Secukinumab is a fully human monoclonal antibody that can selectively neutralize interleukin-17A, and its excellent efficacy has been demonstrated in clinical trials for psoriasis. The aim of our study to assess long-term safety secukinumab 52 weeks real-world practise facility. A total 83 patients (71 with psoriasis vulgaris 12 psoriatic arthritis) were included, 49 them bio-switched patients. Psoriasis Area Severity Index (PASI) 75 PASI-90 responses 80% 64% at week 12, 77% 65% 24, 76% 58%...